Company Overview - Connect Biopharma Holdings Limited Sponsored ADR (CNTB) currently holds a Momentum Style Score of A, indicating strong potential for momentum investing [3] - The company has a Zacks Rank of 2 (Buy), which is supported by a historical track record of outperforming the market [4] Price Performance - CNTB shares have increased by 29.07% over the past week, significantly outperforming the Zacks Medical - Biomedical and Genetics industry, which rose by 1.8% during the same period [6] - Over the past month, CNTB's price change is 65.09%, compared to the industry's 5.63% [6] - In the last quarter, CNTB shares have surged by 120.96%, and over the past year, they have gained 47.06%, while the S&P 500 has only moved 14.96% and 18.01%, respectively [7] Trading Volume - The average 20-day trading volume for CNTB is 262,215 shares, which serves as a bullish indicator when combined with rising stock prices [8] Earnings Outlook - In the past two months, one earnings estimate for CNTB has moved higher, while none have moved lower, resulting in an increase in the consensus estimate from -$1.12 to -$0.90 [10] - For the next fiscal year, one estimate has also moved upwards with no downward revisions during the same period [10] Conclusion - Given the strong price performance, positive earnings outlook, and high Momentum Style Score, CNTB is positioned as a promising investment opportunity [12]

Core Insights - Connect Biopharma has expanded its Board of Directors from six to seven members with the appointment of Jim Schoeneck, who brings over 40 years of experience in drug development and commercialization [1][2][3] Company Overview - Connect Biopharma is a clinical-stage biopharmaceutical company focused on transforming care for asthma and chronic obstructive pulmonary disease (COPD) [4] - The company is advancing rademikibart, a next-generation antibody targeting IL-4Rα, currently undergoing global clinical studies for treating acute exacerbations of asthma and COPD [4] Leadership and Expertise - Jim Schoeneck's appointment is expected to enhance the company's strategic and commercial capabilities, particularly in advancing the development and commercialization of rademikibart [2][3] - Schoeneck has held leadership positions in various biotech firms and has a strong background in guiding companies through significant transformations [3] Product Development - Rademikibart is positioned to address the needs of millions of patients with asthma or COPD who experience acute exacerbations annually [2] - The company anticipates clinical data from its Phase 2 Seabreeze STAT studies in the first half of 2026 [2]

Core Viewpoint - Connect Biopharma Holdings Limited plans to terminate its American Depositary Receipt (ADR) program and convert its ADRs into ordinary shares, which will be listed on the Nasdaq Global Market, enhancing institutional visibility and eliminating depositary fees [1][2][4]. Group 1: Termination of ADR Program - The ADR program and the Deposit Agreement are expected to terminate on or about September 2, 2025, with a mandatory cancellation and exchange of ADRs for ordinary shares at a one-for-one ratio [2]. - A termination notice will be issued to ADR owners around August 18, 2025, providing further details on the termination [3]. Group 2: Strategic Implications - The termination of the ADR program is seen as a significant step towards becoming a U.S.-centric company, which is expected to facilitate institutional visibility and strengthen the investor base [4]. - The conversion to ordinary shares is anticipated to eliminate ADR depositary fees, thereby potentially increasing shareholder value [4]. Group 3: Company Overview - Connect Biopharma is a clinical-stage biopharmaceutical company focused on developing treatments for asthma and COPD, with its lead product candidate, rademikibart, currently undergoing global clinical studies [5]. - The company has an exclusive collaboration agreement for rademikibart with Simcere in China, indicating its strategic partnerships in key markets [5].

Core Viewpoint - Connect Biopharma Holdings Limited is actively participating in the BTIG Virtual Biotechnology Conference, highlighting its focus on transforming care for inflammatory diseases, particularly asthma and COPD [1][3]. Company Overview - Connect Biopharma is a clinical-stage biopharmaceutical company headquartered in San Diego, California, dedicated to developing treatments for asthma and COPD [3]. - The company is advancing rademikibart, a next-generation antibody targeting IL-4Rα, currently undergoing global clinical studies for treating acute exacerbations of asthma and COPD [3]. - Connect Biopharma has an exclusive license and collaboration agreement for rademikibart with Simcere in China [3]. Event Details - The management of Connect Biopharma will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on July 29, 2025, at 9:20 a.m. ET [1]. - A live webcast of the event will be available on the company's website, with an archived replay accessible for approximately 90 days post-event [2].

Core Viewpoint - Connect Biopharma has regained compliance with Nasdaq's minimum bid price requirement, allowing its American Depositary Shares to continue trading on the exchange [1][2]. Company Overview - Connect Biopharma is a clinical-stage biopharmaceutical company focused on treating inflammatory diseases, particularly asthma and chronic obstructive pulmonary disease (COPD) [3]. - The company is advancing rademikibart, a next-generation antibody targeting IL-4Rα, and is conducting global clinical studies for its treatment of acute exacerbations of asthma and COPD [3]. - Connect Biopharma has an exclusive license and collaboration agreement for rademikibart with Simcere in China [3].

Core Viewpoint - Connect Biopharma's collaborator, Simcere Pharmaceutical, has submitted a New Drug Application for rademikibart to treat atopic dermatitis in China, indicating significant progress in the development of this potential best-in-class therapy for inflammatory diseases [1][2]. Company Overview - Connect Biopharma is a clinical-stage biopharmaceutical company focused on developing innovative therapies for inflammatory diseases, with rademikibart as its lead product candidate targeting IL-4Rα [6]. - Simcere Pharmaceutical is an R&D-driven company focusing on therapeutic areas such as neuroscience, anti-oncology, autoimmune, and anti-infection [5]. Product Development - Rademikibart is a fully human monoclonal antibody that targets IL-4Rα, blocking the Th2 inflammatory pathway, which is relevant for treating atopic dermatitis and asthma [4]. - The AD market in China presents a considerable opportunity, with an estimated 70 million patients suffering from the condition [3]. Collaboration Agreement - In 2023, Connect Biopharma and Simcere entered an exclusive license and collaboration agreement for rademikibart in Greater China, granting Simcere exclusive rights for development, manufacturing, and commercialization [2][3]. - Connect Biopharma is eligible for milestone payments totaling approximately $110 million and tiered royalties on net sales in Greater China [3].

Rademikibart Clinical Development and Market Opportunity - Rademikibart shows the largest improvement in FEV observed with a biologic in asthma patients, with a 312 mL increase at 1-week and 420 mL at 24-weeks in patients with baseline eosinophils ≥300 cell/µL[9] - Market research indicates that acute exacerbation indications in asthma and COPD differentiate rademikibart from dupilumab and other biologics, potentially leading to greater chronic use[7, 9] - Projected worldwide peak sales for rademikibart with acute and chronic indications are >$3 billion for asthma and >$2 billion for COPD[7, 9, 25] - Connect has initiated parallel Phase 2 studies in asthma and COPD patients experiencing acute exacerbations, with data expected in 1H2026 and cash runway into 2027[7, 9, 11, 74] Rademikibart Differentiation and Efficacy - Rademikibart is a next-generation anti-IL-4Rα antibody with potential for less frequent dosing, greater sustained efficacy data, and faster onset observed in asthma trials[6, 27] - Home daily lung function data demonstrated 73% of FEV1 improvement seen on Day 7 was observed by Day 1, with 113% by Day 2[41, 42] - In a Phase 2b study, rademikibart significantly improved lung function at Week 12, with enhanced efficacy over placebo in high eosinophil patients (baseline ≥150 cells/µL)[47, 48] - Analysis of COPD-like patients from the global Phase 2b asthma study showed FEV1 change from baseline of 285 mL with Rademikibart 150 mg and 694 mL with Rademikibart 300 mg in all EOS levels[53] Financial Position and Exclusivity - The company has cash, cash equivalents, and short-term investments of $83995000 as of March 31, 2025, expected to support planned operations into 2027[74, 75] - Rademikibart exclusivity extends through at least 2040, supporting substantial growth and value creation[9, 67, 68]

Core Insights - Rademikibart has shown significant improvements in lung function and asthma control for patients with eosinophilic-driven type 2 asthma [1][2] - The treatment has led to a reduction in annualized exacerbation rates in the same patient group [1][10] - Ongoing Phase 2 studies for acute exacerbations in asthma and COPD are expected to report topline data in the first half of 2026 [1] Company Overview - Connect Biopharma is a clinical-stage biopharmaceutical company focused on asthma and COPD treatment [6] - The company is advancing rademikibart, a next-generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody [6] - Rademikibart targets acute exacerbations, addressing a significant unmet need among asthma and COPD patients [6] Clinical Data Highlights - In a Phase 2b trial, rademikibart improved prebronchodilator forced expiratory volume in one second (FEV1) within one week, sustained through 24 weeks [3] - The treatment showed greater improvement in patients with elevated baseline eosinophil counts compared to the overall population [3] - Rademikibart demonstrated a 63% reduction in annualized asthma exacerbation rates (AAER) in patients with elevated eosinophils, 69% in those with elevated FeNO, and 74% in patients with both markers [10]

Summary of Connect Biopharma Holdings (CNTB) Conference Call Company Overview - Connect Biopharma Holdings (CNTB) is undergoing a transformation referred to as "Connect 2.0" with a new management team focused on drug development and regulatory activities [3][4] - The lead program is retimicobart, a next-generation IL-4 receptor alpha monoclonal antibody, positioned as a second-generation alternative to Dupixent [3][4] Core Product Insights - Retimicobart shows a significant improvement in FEV1, a key measure of airway function, with one of the largest improvements seen in biologics for asthma trials [4][5] - The onset of effect occurs within 24 hours, allowing for evaluation in acute settings rather than traditional chronic studies [5][6] - There are over 1 million asthma and 1.3 million COPD patients visiting ERs annually due to acute exacerbations, indicating a substantial market opportunity [5][9] Market Opportunity - Current biologics do not have indications for acute exacerbations, creating a "white space" for retimicobart [6][22] - Market research indicates that the novel acute indication could drive significant chronic use, with a preference share of 40%-45% for acute use and 75% for chronic treatment following acute administration [10][22] - The product is expected to have a multi-billion dollar commercial potential with both acute and chronic indications [23][30] Clinical Development - Two parallel trials (cbreeze stat) for asthma and COPD are underway, with data expected in the first half of the following year [15][16] - The acute studies are designed to assess improvements in FEV1 and reduce hospitalization rates, with a focus on cost savings for hospitals [16][30] - The company has received FDA clearance to move into phase three for atopic dermatitis, pending completion of a partner study in China [21][24] Financial Considerations - Development costs for acute indications are estimated at around $50 million, while combined acute and chronic programs could reach $200 million [29] - The company has sufficient cash reserves to execute its plans into 2027, allowing for strategic development without immediate dilution [24][30] Regulatory Landscape - There is no precedent for acute indications in the biologics market, presenting both challenges and opportunities for Connect Biopharma [33] - Extensive discussions with the FDA have provided insights into potential pathways for approval [33] Conclusion - Connect Biopharma is positioned to leverage its innovative product retimicobart in a largely untapped market for acute asthma and COPD treatment, with a strong focus on rapid clinical development and strategic partnerships to enhance its market presence [22][30]

Summary of Connect Biopharma Holdings (CNTB) Conference Call - June 04, 2025 Company Overview - Connect Biopharma is undergoing a transformation referred to as "Connect 2.0" with a new management team experienced in drug development and public biotech operations [2][22] - The company is focusing on retimicobart, a second-generation IL-4 receptor alpha monoclonal antibody, targeting asthma and COPD [2][3] Key Developments - Two parallel Phase II studies have been initiated for retimicobart, specifically addressing acute exacerbations in asthma and COPD [2][3] - The company has sufficient cash to fund these studies, with a runway extending into 2027 [3][22] - The headquarters has been relocated to San Diego, reducing the company's footprint in China to become more U.S.-centric [3] Market Opportunity - Market research indicates that having an acute indication for retimicobart could create a market opportunity exceeding $5 billion globally [4] - There are over 2 million emergency department visits annually in the U.S. for asthma and COPD exacerbations, highlighting a significant patient population [5][8] - Current treatments for acute exacerbations are largely unchanged from two decades ago, primarily involving steroids and bronchodilators, which take hours to stabilize patients [24][25] Product Differentiation - Retimicobart is positioned uniquely as no other biologic currently has an acute indication for asthma or COPD [4][6] - The product has shown rapid onset of action, with over 70% of the benefit observed within 24 hours of administration [5][13] - The company aims to reduce emergency room visits and hospitalizations, potentially shortening hospital stays and providing cost savings for healthcare systems [28][29] Clinical Data - Previous Phase II studies indicated significant improvements in respiratory function (FEV1) with retimicobart, showing an average improvement of 420 ml at 24 weeks [4][12] - The product demonstrated a rapid improvement in airway function, with 73% of the benefit observed within 24 hours [13][16] - The company has a differentiated safety profile compared to Dupixent, particularly in patients with high eosinophil counts [17][20] Financial Position - As of March, the company reported a cash position of nearly $84 million, sufficient to fund ongoing Phase II programs [22] - The exclusivity for retimicobart extends well into 2040, providing a long-term competitive advantage [20] Future Catalysts - Results from the two Phase II trials are expected in the first half of next year, with ongoing preclinical data supporting the product's differentiation [33][32] - The company is also developing a separate product for hospital use to enhance economic viability and fit within existing reimbursement structures [30] Conclusion - Connect Biopharma is strategically positioned to address significant unmet needs in the treatment of acute asthma and COPD exacerbations, with a strong focus on rapid onset of action and cost-effectiveness for healthcare providers [28][29][30]